Tirzepatide dosing follows a slow, fixed ramp. The labeled brand for weight management starts at 2.5 mg once weekly for four weeks, then rises in 2.5 mg steps no sooner than every four weeks, up to a maximum of 15 mg. That is the whole chart in one sentence. The steps exist to let the stomach adjust, not to reach a target fast, and skipping ahead usually buys nausea rather than faster results.
What does the labeled schedule actually look like?
For the weight-management brand, the prescribing information sets a predictable path. Week one through four is 2.5 mg once weekly. If that is tolerated, the dose moves to 5 mg for the next four weeks. From there the label allows increases of 2.5 mg every four weeks as needed, through 7.5 mg, 10 mg, 12.5 mg, and 15 mg. The full detail sits in the ZEPBOUND prescribing information, and the diabetes brand follows a closely related structure in the MOUNJARO labeling.
The single most misread part is the 2.5 mg opening. It is a lead-in dose, and the label says plainly it is not meant for weight reduction. People often feel discouraged that a month at 2.5 mg does little. That is the design working, not failing.
Why is the ramp so slow?
The gut is the reason. Tirzepatide slows stomach emptying, and the common early effects, nausea, constipation, and occasional vomiting, track closely with how fast the dose climbs. A slower titration gives the digestive system time to settle at each level. In the SURMOUNT-1 trial, which followed adults over 72 weeks, gastrointestinal effects were most common during dose escalation and generally eased once a dose was held steady. The trial results are summarized in the SURMOUNT-1 publication.
This is why a good prescriber will hold a dose longer, or even step back down, when side effects are rough. There is no medal for reaching 15 mg on schedule. The schedule is a ceiling on speed, not a quota.
How high does anyone actually need to go?
Not everyone reaches the top step, and not everyone should. In SURMOUNT-1, all three maintenance doses, 5 mg, 10 mg, and 15 mg, produced substantial weight change, with higher doses tending to produce more. But the difference between a tolerated 10 mg and a poorly tolerated 15 mg is not obviously in the higher dose’s favor for a given person.
Other trials fill in the picture. The SURMOUNT-CN study in Chinese adults with obesity confirmed meaningful reduction at the studied doses, and a 2024 head-to-head, published as semaglutide versus tirzepatide for weight loss, found greater average loss with tirzepatide over the period studied. The obstructive sleep apnea trial showed benefit beyond weight alone. The practical takeaway across all of them is that the right dose is the lowest one that gets an individual to their goal and stays tolerable.
What happens when you reach a maintenance dose?
Maintenance is not the finish line, it is the long middle. The SURMOUNT-4 trial looked at what happens after the titration is done: people who continued tirzepatide kept most of their weight reduction, while those switched to placebo regained a large share of it. That finding shapes how the chart should be read. The dose you settle on is meant to be ongoing, not a course you complete and stop.
Brand steps versus compounded products
The chart above describes the FDA-approved brands. Compounded tirzepatide is a different situation, and worth being clear about.
| Feature | Approved brand | Compounded product |
|---|---|---|
| Approval status | FDA-approved | Not FDA-approved |
| Dose steps | Fixed 2.5 mg increments on the label | Set by the prescriber and pharmacy, may differ |
| Concentration | Standardized per pen | Varies by pharmacy |
| Evidence base | The published trials above | Not the direct subject of those trials |
Because a compounded product is prepared by a pharmacy rather than made under an approved application, its concentration and dosing may not line up with the labeled steps, and its schedule should come only from the clinician who prescribed it. A 2024 pharmacovigilance analysis, the FDA adverse event reporting study of compounded GLP-1 products, and a 2025 provider review, navigating compounded semaglutide, both flag dosing errors as a recurring risk with compounded versions, often from confusion over concentration. That is the practical reason not to treat a brand chart as interchangeable.
Cost is usually the reason people look at compounded options at all, and the field is wide: Ro, Hims and Hers, Henry Meds, and LillyDirect all sit somewhere in it. Some supervised telehealth practices, including FormBlends, publish a flat-price tirzepatide dosage chart alongside their pricing so a beginner can see the titration plan before committing. Any such chart still needs a prescriber to confirm it fits the actual product dispensed.
What should a beginner do with all this?
Read the chart as a floor on patience, not a target to rush. Start at 2.5 mg, expect the first month to feel like little is happening, and raise the dose only when the current one feels manageable. Tell the prescriber early if nausea is interfering with eating or hydration, because holding a dose is a normal, sensible move. And if a compounded product is involved, get the dosing in writing from the person who prescribed it rather than reading it off a brand schedule.
Key takeaways
- The labeled ramp is 2.5 mg to start, then 2.5 mg steps no sooner than every four weeks, up to 15 mg.
- The 2.5 mg opening month is a lead-in, not a weight-loss dose.
- Many people do well at 10 mg and never need the top step.
- Compounded tirzepatide is not FDA-approved and may not follow the brand’s concentrations or steps.
See also: Law Firms: Competitive Insights Guide for The Defenders
Frequently asked questions
What is the standard starting dose of tirzepatide?
The labeled starting dose for the weight-management brand is 2.5 mg once weekly for four weeks. That first month is a lead-in meant to reduce stomach side effects rather than to drive weight loss, and the dose rises only after it.
How fast can the dose be increased?
The labeling raises the dose in 2.5 mg steps no sooner than every four weeks. Some people move up faster than others, and staying on a tolerated dose longer is allowed and often sensible.
What is the highest tirzepatide dose?
The maximum labeled maintenance dose is 15 mg once weekly. Many people reach their goals at a lower step, such as 10 mg, and there is no requirement to climb to the top.
Is a compounded tirzepatide chart the same as the brand chart?
No. Compounded tirzepatide is not an FDA-approved product, so its concentrations and dosing may not match the labeled brand steps. Any dosing for a compounded product should come from the prescriber who wrote it.
What should a beginner check before starting?
Whether the plan is to follow the labeled titration schedule, who adjusts the dose, and how side effects are handled. A dosing chart is a starting reference, not a self-management instruction.
